title: Cysteine protease production by human osteosarcoma cells (MG63, SAOS2) and its modulation by soluble factors.
abstract: The production of cysteine protease by two human osteosarcoma cell lines (MG-63 and SaOS2) was analyzed, as well as their modulation by interleukin 1beta (hIL-1 beta), interleukin 6 (hIL-6), insulin growth factor-1 (hIGF-1), oncostatin M (hOSM), leukemia inhibitory factor (hLIF) and growth hormone (hGH). Cysteine protease activities were detected using a synthetic substrate. The protease activities (especially cathepsin L activity) of both cell lines were increased significantly in the presence of hIL-1 beta, hIL-6 and hOSM. In contrast, hIGF-1 and hGH decreased these activities, and no effect was detectable in the presence of hLIF. The addition of antibodies against the gp-130 chain of the hIL-6 and hOSM receptors totally inhibited the stimulating effect of these two cytokines on cysteine protease activities. In increasing collagen type I degradation, hIL-1beta, hIL-6 and hOSM could be involved in bone resorption, whereas the inhibitory action of hIGF-1 and hGH on collagen type I degradation suggest that this factor could play a role in bone formation.
authors.affiliation: Laboratorie de physiopathologie de la résorption osseuse et mécanismes de cicatrisation, Faculté de Chirurgie Dentaire, Nantes, France.
authors.forename: C
authors.initials: C
authors.lastname: Damiens
authors.forename: E
authors.initials: E
authors.lastname: Grimaud
authors.forename: A V
authors.initials: AV
authors.lastname: Rousselle
authors.forename: C
authors.initials: C
authors.lastname: Charrier
authors.forename: Y
authors.initials: Y
authors.lastname: Fortun
authors.forename: D
authors.initials: D
authors.lastname: Heymann
authors.forename: M
authors.initials: M
authors.lastname: Padrines
mesh_terms: D002401:Cathepsin B / Q000096:biosynthesis*; D056668:Cathepsin L; D002403:Cathepsins / Q000096:biosynthesis*; D003546:Cysteine Endopeptidases / Q000096:biosynthesis; D010450:Endopeptidases; D013006:Growth Hormone / Q000494:pharmacology; D006131:Growth Inhibitors / Q000494:pharmacology; D019382:Human Growth Hormone; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000494:pharmacology; D053683:Oncostatin M; D012516:Osteosarcoma; D010455:Peptides / Q000494:pharmacology; D012995:Solubility; D014407:Tumor Cells, Cultured
chemical_list: D006131:Growth Inhibitors; D007375:Interleukin-1; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; C508351:OSM protein, human; D010455:Peptides; D053683:Oncostatin M; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D002403:Cathepsins; D010450:Endopeptidases; D003546:Cysteine Endopeptidases; D002401:Cathepsin B; C534281:CTSL protein, human; D056668:Cathepsin L